This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Available from: [link] About the author Cliff Brass, MD PhD FAASLD, Chief Medical Officer at Resolution Therapeutics Cliff Brass is an expert in clinicaldevelopment with special expertise in liver disease and over 25 years of experience in pharma. He is named on 15 patents relating to drug development in liver disease.
has been appointed Senior Vice President and Head of the Company’s Vaccine Research & Development (R&D) organization effective August 1, succeeding Kathrin U. Anderson most recently served as Vice President and Chief Scientific Officer for Bacterial Research and Hospital within the Vaccine R&D organization.
Roy Baynes, Senior Vice President and Head of Global ClinicalDevelopment, Chief Medical Officer at MSD ResearchLaboratories, said: “HRD is an important biomarker of advanced ovarian cancer that can inform how physicians in the EU treat this aggressive type of cancer. months versus 35.3 months with bevacizumab.
“While the treatment landscape has evolved, an unmet need remains for appropriate patients newly diagnosed with certain types of advanced urothelial carcinoma who are not eligible for platinum-containing chemotherapy,” said Dr. Scot Ebbinghaus, vice president, clinicalresearch, Merck ResearchLaboratories. “We
Hyman currently serves as director of the Stanley Center for Psychiatric Research at the Broad Institute of MIT and Harvard and is the Harvard University Distinguished Service Professor of Stem Cell and Regenerative Biology. Evenstad served as chief executive officer of Upsher-Smith Laboratories.
Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Kumquat Biosciences today announced an exclusive collaboration focused on the discovery, development and commercialization of potential novel small molecules that stimulate tumor-specific immune responses.
This collaboration with the Lieber Institute further expands our innovative neuropsychiatric research program, a key focus area at Boehringer Ingelheim, with a first-in-class mechanism that may have the potential to address these symptoms,” said Dr. Hugh Marston, Ph.D., Head of Department CNS Diseases Research at Boehringer Ingelheim. “By
The data were presented at the 2021 American Association for Cancer Research (AACR) Annual Meeting, held virtually April 10-15, 2021. Loxo Oncology at Lilly was created in December 2019, combining the Lilly ResearchLaboratories oncology organization and Loxo Oncology, which was acquired by Lilly in early 2019.
Cadavid will be responsible for the strategy, direction and execution of the company’s clinicaldevelopment programs. Prior to Fulcrum, Cadavid held several leadership positions at Biogen, including Senior Medical Director of the multiple sclerosis clinicaldevelopment group. He spent 27 years at Merck & Co.
Most importantly, we are continuing to see patients benefit from the profound therapeutic effects of both approved products and those currently in clinicaldevelopment. These manufactured antibodies have been developed and manufactured by Eli Lilly and Company ’s Lilly ResearchLaboratories in a partnership with AbCellera.
Loxo Oncology at Lilly was created in December 2019, combining the Lilly ResearchLaboratories oncology organization and Loxo Oncology, which was acquired by Lilly in early 2019. Our approach centers on creating new oncology medicines that unequivocally work early in clinicaldevelopment and will matter to patients.
“We are pleased to offer two potential new treatment options with KEYTRUDA for patients in Japan based on compelling data from our clinical trial program,” said Dr. Roy Baynes, senior vice president and head of global clinicaldevelopment, chief medical officer, Merck ResearchLaboratories.
“There is a real need to advance new treatment options for triple-negative breast cancer, an aggressive form of the disease,” said Roy Baynes, senior vice president and head of global clinicaldevelopment, chief medical officer, Merck ResearchLaboratories, in July 2020.
We strongly believe in the results of the PROpel trial, which demonstrated the clinically meaningful benefit for this combination in a broad population of patients regardless of biomarker status.”
Baynes, head of Global ClinicalDevelopment (GCD) and Chief Medical Officer, Merck ResearchLaboratories (MRL), will be retiring from Merck in July. Li, president, Merck ResearchLaboratories, until his retirement. He also led the expansion of Merck’s research and development in China and Japan. “It
It is very clear that in this study, the addition of ipilimumab did not add clinical benefit but did add toxicity. Merck and Eisai are committed to working together to continue to explore the potential of the KEYTRUDA plus LENVIMA combination, particularly in areas of great unmet need such as renal cell carcinoma.”. “We
Merck will assist with preclinical development and has the option to exclusively develop, manufacture and commercialize the candidate following Phase 1. “In Perlmutter, President, Merck ResearchLaboratories. “We
“We continue to make progress in our Phase 2/3 clinical programs evaluating molnupiravir in both outpatient and hospital settings and plan to provide updates when appropriate,” said Dr. Roy Baynes, senior vice president and head of global clinicaldevelopment, chief medical officer, Merck ResearchLaboratories.
“These highly anticipated event-free survival results in this TNBC population build upon earlier findings from the KEYNOTE-522 trial and further support the potential use of KEYTRUDA in these patients,” said Dr. Vicki Goodman, vice president, clinicalresearch, Merck ResearchLaboratories.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of data from the company’s HIV clinicaldevelopment program at the 11th International AIDS Society Conference on HIV Science (IAS 2021) from July 18-21. Our Commitment to HIV.
We hope to build on this important research and provide new treatment options to kidney cancer patients.”. “As The late-breaking results will be presented in the Plenary session of the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract #LBA5) on Sunday, June 6, 2021. KEYTRUDA is currently approved in the U.S.,
“Since its first approval in renal cell carcinoma nearly two years ago, KEYTRUDA has become an important first-line treatment option in combination with axitinib for patients with advanced renal cell carcinoma,” said Dr. Roy Baynes, senior vice president and head of global clinicaldevelopment, chief medical officer, Merck ResearchLaboratories.
“We are delighted to share our early data at CROI 2021 supporting the potential for a once-yearly dosing regimen for islatravir using a subdermal implant,” said Dr. Joan Butterton, vice president, global clinicaldevelopment, infectious diseases, Merck ResearchLaboratories. “We Our Commitment to HIV.
“The FDA’s acceptance of our application adds to our momentum of advancing new treatment options to address the most challenging cancers facing women,” said Dr. Scot Ebbinghaus, vice president, clinicalresearch, Merck ResearchLaboratories. Merck has the industry’s largest immuno-oncology clinicalresearch program.
“It continues to be critically important to advance potential antiviral treatments to address the devastating impact of COVID-19 globally,” said Dr. Roy Baynes, senior vice president and head of global clinicaldevelopment, chief medical officer, Merck ResearchLaboratories. “If
“Some adults, including older adults or those with certain chronic medical conditions or immunocompromising conditions, are at increased risk for pneumococcal disease and its serious, sometimes life-threatening complications,” said Dr. Jose Cardona, Indago Research and Health Center, coordinating investigator for the PNEU-AGE trial.
Eliav Barr, senior vice president, head of global clinicaldevelopment and chief medical officer, Merck ResearchLaboratories, said, “It is imperative that we create new ways to treat advanced cancers and help improve patient outcomes by building on the current standard of care.
All clinical studies provide important learnings to help us in the fight against HIV, and we are grateful to the patients and investigators for their contributions.”. mg daily (DOR/ISL) in HIV-1 virologically suppressed participants. Source link: [link].
“There remains a significant unmet need for patients diagnosed with advanced prostate cancer, who have a poor prognosis after not responding to initial therapy,” said Dr. Roy Baynes, senior vice president and head of global clinicaldevelopment, chief medical officer, Merck ResearchLaboratories. Source link: [link].
“Pneumococcal disease in adults is on the rise globally, in part driven by disease-causing serotypes not targeted by the currently available pneumococcal conjugate vaccine,” said Dr. Roy Baynes, senior vice president and head of global clinicaldevelopment, chief medical officer, Merck ResearchLaboratories.
These data were shared as a late-breaking oral presentation during the virtual 11 th International AIDS Society Conference on HIV Science (IAS 2021) and are a follow-up to the interim analysis that was presented earlier this year at the virtual 2021 HIV Research for Prevention Conference (HIVR4P 2021). Our Commitment to HIV.
“Triple-negative carcinoma grows and spreads faster than other sorts of carcinoma and consequently features a worse prognosis,” said Dr. Vicki Goodman, vice chairman , clinicalresearch, Merck ResearchLaboratories. Merck has the industry’s largest immuno-oncology clinicalresearch program.
We are delighted that PREVYMIS is now approved to help prevent CMV disease in adult kidney transplant patients at high risk,” said Dr. Elizabeth Rhee, vice president, global clinicaldevelopment, Merck ResearchLaboratories. “At Source link: [link]
Gilead Lores, and Merck, known as MSD outside the United States and Canada, moment blazoned the launch of a Phase 2 clinical study assessing an investigational formerly-daily oral combination treatment authority of islatravir and lenacapavir in people living with HIV who are virologically suppressed on antiretroviral remedy.
We strongly believe in the results of the PROpel trial, which demonstrated a clinically meaningful benefit for this combination in a broad population of patients regardless of biomarker status.”
“This announcement reflects another important regulatory milestone in the development of this medicine,” said Dr. Roy Baynes, senior vice president and head of global clinicaldevelopment, chief medical officer, Merck ResearchLaboratories.
Rubin, senior vice president, global clinicaldevelopment, Merck ResearchLaboratories. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. The safety profile of KEYTRUDA was consistent with findings from previous studies.
We are pleased to offer a meaningful new treatment option for appropriate patients with symptomatic chronic heart failure,” said Dr. Roy Baynes, senior vice president and head of global clinicaldevelopment, chief medical officer, Merck ResearchLaboratories.
Lehan Chair in Cardiovascular Research, and professor and president of the department of drug at the University of Mississippi Medical Center. Joerg Koglin, vice chairman, Global ClinicalDevelopment and Therapeutic Area Head, Cardiovascular for Merck ResearchLaboratories. Javed Butler, the PatrickH.
“There have been few advances in improving survival outcomes in the first-line treatment setting for esophageal cancer over the last three decades,” said Dr. Roy Baynes, senior vice president and head of global clinicaldevelopment, chief medical officer, Merck ResearchLaboratories. “We
Gregory Lubiniecki, Vice President, Global ClinicalDevelopment, Merck ResearchLaboratories. Senior Vice President, ClinicalDevelopment, Oncology at Eisai Inc. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines.
Merck has the industry’s largest immuno-oncology clinicalresearch program. The KEYTRUDA clinical program seeks to understand the role of KEYTRUDA across cancers and the factors that may predict a patient’s likelihood of benefitting from treatment with KEYTRUDA, including exploring several different biomarkers.
Baynes, senior vice president and head of global clinicaldevelopment, chief medical officer, Merck ResearchLaboratories. Islatravir is a promising antiviral candidate with evidence from ongoing clinical trials to support its development as a once-monthly oral PrEP agent. Merck’s Commitment to HIV.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content